[Webinar] How to better optimize an oncology drug discovery program
Register for this webinar discussing how conventional and innovative integrated technological skills should be incorporated into an oncology program.Read more
Explore the disease & find out about our strategic R&D collaboration with Servier: info, press releases & video!
Read all the details of the collaboration agreement for R&D of a new personalized cancer treatment for aggressive and untreatable tumors.
Meet Dr. Jan Hoflack during Biotech ShowCase to explore our products pipeline using our technological module Nanocyclix®.
Protection of RIPK2 inhibitors resulting from Nanocyclix® technology with patents granted on the main international markets: Europe, United States, Japan and Eurasia
Under this agreement, Oncodesign will be responsible for identification, chemical synthesis & optimization of Nanocyclix® drug candidates & their early-stage analysis. TiumBio will be responsible for the advanced evaluation of fibrotic efficacy of the drug candidates.
[Press Release] Find the update of the RIPK2 program and the start of new programs associated with Nanocyclix.
Read Press Release the selection of a preclinical candidate resulting from their strategic collaboration to find new treatments for Parkinson’s disease.
Inhibiting Endothelial Cell Function in Normal and Tumor Angiogenesis Using BMP Type I Receptor Macrocyclic Kinase Inhibitors
NANOCYCLIX® ALK2 INHIBITORS TO OVERCOME CANCER INDUCED ANEMIA
Development of Macrocycle Kinase Inhibitors for ALK2 Using Fibrodysplasia Ossificans Progressiva-Derived Endothelial Cells